Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy

References

• Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol 2015;4:365-80
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737-46
   PubMed Web of Science ®Google Scholar
• Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 2016;70:256-62
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163-77
   PubMed Web of Science ®Google Scholar
• James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338-51
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017:377(4):352-60, doi:10.1056/NEJMoa1704174
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Rajan P, Frew JA, Wilson JM, et al. Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. Urol Oncol Semin Orig Investig 2015;33:337.e1-6
   Google Scholar
• Rosenthal SA, Hunt D, Sartor AO, et al. A phase 3 trial of 2 years of androgen suppression and radiation therapy with or without adjuvant chemotherapy for high-risk prostate cancer: final results of radiation therapy oncology group phase 3 randomized trial NRG oncology RTOG 9902. Int J Radiat Oncol Biol Phys 2015;93:294-302
   PubMed Web of Science ®Google Scholar
• Rosenthal SA, Bae K, Pienta KJ, et al. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys 2009;73:672-8
   PubMed Web of Science ®Google Scholar
• Fizazi K, Lesaunier F, Delva R, et al. A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Canc 2012;48:209-17
   PubMed Web of Science ®Google Scholar
• Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 2015;16:787-94
   PubMed Web of Science ®Google Scholar
• Sandler HM, Hu C, Rosenthal SA, et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol 2015;33:LBA5002
   Google Scholar
• Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149-58
   PubMed Web of Science ®Google Scholar
• Vale CL, Burdett S, Rydzewska LHM, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 2016;17:243-56
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Combined chemohormonal strategy in hormone-sensitive prostate cancer: a pooled analysis of randomized studies. Clin Genitourin Cancer 2016;14:203-9
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005
   PubMed Web of Science ®Google Scholar
• Romero I, Garrido C, Algarra I, et al. T lymphocytes restrain spontaneous metastases in permanent dormancy. Cancer Res 2014;74:1958-68
   PubMed Web of Science ®Google Scholar
• Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr Opin Immunol 2014;27:16-25
   PubMed Web of Science ®Google Scholar
• Flaig TW, Plets M, Hussain MHA, et al. Abiraterone acetate for metastatic prostate cancer in patients with suboptimal biochemical response to hormone induction. JAMA Oncol 2017:3;(11):e170231, doi:10.1001/jamaoncol.2017.0231
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67:5033-41
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Nelson PS, Lange P, et al. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol 2014;32:229-37
   PubMed Web of Science ®Google Scholar
• Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166:500-6-7
   PubMed Web of Science ®Google Scholar
• Taplin M-E, Montgomery B, Logothetis CJ, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol 2014;32:3705-15
   PubMed Web of Science ®Google Scholar
• Chopra A, Georgieva M, Lopes G, et al. Abiraterone or enzalutamide in advanced castration-resistant prostate cancer: an indirect comparison. Prostate 2017;77:639-46
   PubMed Web of Science ®Google Scholar
• Boutin B, Tajeddine N, Vandersmissen P, et al. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis. Prostate 2013;73:1090-102
   PubMed Web of Science ®Google Scholar
• Hug V, Thames H, Clark J. Chemotherapy and hormonal therapy in combination. J Clin Oncol 1988;6:173-7
   PubMed Web of Science ®Google Scholar
• Espinosa M, Falcon A, Gutierrez-Valencia A, et al. Pharmacokinetic food-effect study of abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC): the ABIFOOD trial (EudraCt number: 2012-003226-25). J Clin Oncol 2016;34:227
   PubMedGoogle Scholar
• Leibowitz-Amit R, Atenafu EG, Seah J-A, et al. Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): the Princess Margaret Cancer Centre (PM) experience. J Clin Oncol 2014;32:61
   Google Scholar
• Chi K, Protheroe A, Antolin AR, et al. Benefits of abiraterone acetate plus prednisone (AA1 P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (pt) reported outcomes (PRO). Ann Oncol 2017;28:v269-94
   Web of Science ®Google Scholar
• Patrick-Miller LJ, Chen Y-H, Carducci MA, et al. Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa). J Clin Oncol 2016;34:286
   PubMedGoogle Scholar
• Joly F, Gravis G, Oudard S, et al. Patients’ self-assessment of tolerance and quality of life during docetaxel-based chemotherapy: results from a phase III trial in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403). J Clin Oncol 2010;28:9123
   Web of Science ®Google Scholar
• Duran MAC, Mellado B, Rodriguez JMP, et al. Longer time from diagnosis to docetaxel treatment results in a shorter survival in metastatic hormonosensitive prostate cancer (mHSPC) patients treated with chemotherapy 1 androgen deprivation therapy (ADT). Ann Oncol 2017;28:277
   Web of Science ®Google Scholar
• Tagawa ST, Posadas EM, Bruce J, et al. Phase 1b study of abiraterone acetate plus prednisone and docetaxel in patients with metastatic castration-resistant prostate cancer. Eur Urol 2016;70:718-21
   PubMed Web of Science ®Google Scholar